Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.

@article{Friedberg2002CombinationIW,
  title={Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.},
  author={Jonathan W. Friedberg and Donna S Neuberg and John G Gribben and David C. Fisher and Christine M. Canning and Margaret A. Koval and Christine M Poor and Lucinda M. Green and John Alexander Daley and Robert J. Soiffer and Jerome Ritz and Arnold Stephen Freedman},
  journal={British journal of haematology},
  year={2002},
  volume={117 4},
  pages={
          828-34
        }
}
Rituximab has significant activity as a single agent in the treatment of follicular non-Hodgkin's lymphoma (NHL). Interleukin 2 (IL-2) is a lymphokine that increases effector cell number. In an effort to augment antibody-dependent cell-mediated cytotoxicity (ADCC) associated with rituximab therapy, low-dose IL-2 was added to a standard rituximab regimen and patients were evaluated for safety and efficacy. Twenty patients with relapsed or refractory follicular NHL were treated with IL-2 (1.2 MIU… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Similar Papers

Loading similar papers…